News

Pfizer, Novartis get MenB ACIP nod--but not the one they're really after

Pfizer and Novartis officially have a nod from the CDC's Advisory Committee on Immunization Practices (ACIP) for their recently approved meningitis B vaccines. Problem is, it doesn't cover nearly as large a population as the pharma giants would like.

Valeant touts PhII Provenge data following Dendreon buy

Valeant only just picked up Provenge and other assets from bankrupt Dendreon, but it's already trumpeting positive preliminary data for the flailing cancer vaccine. On Wednesday, it announced Phase II results showing that the immune response from Provenge continues two years after biochemically recurrent prostate cancer patients complete treatment.

NewLink nets $20M Ebola milestone from Merck

NewLink's Ebola vaccine tie-up with Merck continues to pay off.

Combo of Bavarian Nordic's Prostvac and BMS' Yervoy yields promising PhI results

On Tuesday, Bavarian Nordic announced positive survival data from a Phase I combination study of its active prostate cancer immunotherapy candidate Prostvac and Bristol-Myers Squibb's Yervoy (ipilimumab), an immune checkpoint inhibitor.

Takeda places vaccines unit in Singapore to push for global growth

Last September, Takeda announced it would be putting vaccines into their own specialty business unit to "accelerate the globalization" of the business. And now, it's positioning the unit geographically to do the same.

UPDATED: Serum Institute and Bharat Biotech race to get swine flu vaccines back on the market

Swine flu is making a comeback in India, and with a vengeance. After destroying their existing stocks due to poor demand and short shelf life, Serum Institute and Bharat Biotech will be racing to get their swine flu vaccines back on the market.

Pfizer trumpets positive Trumenba data ahead of ACIP vote

Pfizer may have FDA approval for meningitis B vaccine Trumenba, but it can only take the jab so far without a nod from the CDC's Advisory Committee on Immunization Practices (ACIP). Now, though, it's got some positive new data on the shot just in time to help it make its case for one.

HIV vaccine trial kicks off in South Africa

Researchers have launched a clinical trial in South Africa--dubbed HVTN 100--to evaluate a candidate HIV vaccine regimen for safety and the immune response it triggers.

Advaxis nets $23M in financing for cancer vaccine development

Advaxis is pushing full steam ahead to test its cancer vaccine candidates in immunotherapy combos, and it just scored another $23 million to help its hopefuls through the clinic.

VaxInnate reaps $53M for flu jab trials on BARDA contract extension

The U.S. Department of Health and Human Services apparently likes what it's seen from a 5-year contract with VaxInnate. Its Biomedical Advanced Research and Development Authority (BARDA) has extended the contract's base period with the flu vaccine maker, a move that allows for the use of $53 million.

Novavax's Ebola vaccine is in hot pursuit of GSK, Merck, J&J candidates

Novavax announced on Thursday that it would take its Ebola candidate to Australia for a Phase I trial involving 230 healthy adults. It is the fourth company to bring an Ebola vaccine to human trials, but Novavax says it has a better vaccine.

Protein Sciences halts Connecticut expansion in response to governor's use of rival flu shot

Flu vaccine maker Protein Sciences may be abandoning its expansion plans in Connecticut, opting instead to build out its New York-based manufacturing site. But it's not for any of the reasons one might expect.

Gates Foundation, WHO fund synthetic polio vaccine development

Only a few hundred cases of polio are reported each year, but a synthetic vaccine could be the key to eradicate it for good. Scientists are teaming up to develop a synthetic vaccine in an effort to address some limitations of the existing oral vaccine.

Advaxis inks pact with Incyte to test cervical cancer vaccine combo

Advaxis, on a partnering spree after joining with Merck and AstraZeneca to test its cancer vaccine candidates in immunotherapy combos, has teamed up with Incyte to trial one of its prospects in cervical cancer.

Vaxxas scores $20M to develop needle-free vaccines

Vaxxas announced Monday that it raised $20 million in a Series B round, which will be used to advance a series of clinical programs and to develop a pipeline of new vaccine products using the company's needle-free Nanopatch platform.

GSK nabs pipeline prospects, conjugate vaccine tech with GlycoVaxyn buyout

Since forging a scientific collaboration in 2012, GlaxoSmithKline has held a minority stake in Swiss biotech GlycoVaxyn. Now, it's forking over $190 million to acquire the remaining shares and take full ownership of the company.

Serum Institute and Cipla in early merger talks

Serum Institute of India and Cipla already have an agreement to distribute the former's low-cost vaccines in Europe, but the partnership may not stop there. The two India-based companies have held preliminary discussions on a possible merger, said Cyrus Poonawalla, chairman of Serum Institute.

GSK lays off 27 vaccine researchers in Montana

As GlaxoSmithKline prepares to fold in the bulk of Novartis' vaccines unit--headed its way after their April 2014 multibillion-dollar asset swap--it's changing things up a little. And that includes closing the R&D branch of its vaccines lab in Hamilton, MT, this year.

UPDATED: Valeant grabs Provenge and other Dendreon assets with raised $400M bid

It's official: Valeant will be the new owner of Dendreon's Provenge.

Scientists in search of next-generation Ebola vaccines as outbreak dwindles

The current Ebola outbreak may be starting to wane, but scientists agree they'll need a stockpile of vaccines to tackle the next one. And that means developing next-generation shots that can fight off multiple strains.